Aktis Oncology, Inc. Common stock (AKTS) Stock
Key stats
- Market cap
- $913.27M
- Price / Earnings ratio
- -14.0x
- EPS (TTM)
- -$12.24
- Volume
- Loading
- 52-week high
- $34.19
- 52-week low
- $14.72
Source: third-party data provider, as of October 23, 2026
Compare with AKTS
Recent news
Bank of America Sees Bargains in These 16 Knocked-Down AI Stocks
Bank of America Sees Bargains in These 16 Knocked-Down AI Stocks
AKTS
Wall Street Analysts Predict a 74.73% Upside in Aktis (AKTS): Here's What You Should Know
Wall Street Analysts Predict a 74.73% Upside in Aktis (AKTS): Here's What You Should Know
AKTS
Huge Insider Buying Now at This Insurance Giant and 2 Biotechs
Huge Insider Buying Now at This Insurance Giant and 2 Biotechs
AKTS
A Fresh IPO That Long-Term Investors Shouldn't Ignore
A Fresh IPO That Long-Term Investors Shouldn't Ignore
AKTSTechnical indicators
- RSI 14
- 36.51
- MACD 12/26/9
- -1.58
- EMA 9 of MACD
- -1.69
- MACD histogram
- 0.11
- SMA 50
- $21.57
- Price below SMA 50
- EMA 50
- $20.18
- Price below EMA 50
Calculated by Gotrade from daily closing prices, as of October 22, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 3 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
No data available
Debt & Balance Sheet
No data available
Revenue to Profit
No data available
Earnings
No data available
Source: third-party data provider
Latest news
Bank of America Sees Bargains in These 16 Knocked-Down AI Stocks
Bank of America Sees Bargains in These 16 Knocked-Down AI Stocks
AKTSWall Street Analysts Predict a 74.73% Upside in Aktis (AKTS): Here's What You Should Know
Wall Street Analysts Predict a 74.73% Upside in Aktis (AKTS): Here's What You Should Know
AKTSHuge Insider Buying Now at This Insurance Giant and 2 Biotechs
Huge Insider Buying Now at This Insurance Giant and 2 Biotechs
AKTSA Fresh IPO That Long-Term Investors Shouldn't Ignore
A Fresh IPO That Long-Term Investors Shouldn't Ignore
AKTS
Vida Ventures Congratulates Aktis Oncology on Its Entry into the Public Markets
Vida Ventures Congratulates Aktis Oncology on Its Entry into the Public Markets
AKTS
Aktis Oncology prices upsized US IPO at $18 per share
Aktis Oncology prices upsized US IPO at $18 per share
AKTS
3 Stocks No One in Their Right Mind Would Own Right Now: June Edition
3 Stocks No One in Their Right Mind Would Own Right Now: June Edition
AKTS
Insider Favorites: 7 Stocks with Bullish Buying Signals
Insider Favorites: 7 Stocks with Bullish Buying Signals
AKTS
2 Radio Frequency Stocks to Watch in a Challenging Industry
2 Radio Frequency Stocks to Watch in a Challenging Industry
AKTSAbout Aktis Oncology, Inc. Common stock
The company is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The field of targeted radiopharmaceuticals is currently led by two marketed products that have demonstrated transformative survival outcomes and meaningful quality-of-life benefits through the delivery of radioisotopes to solid tumors. These leading products, which target prostate-specific membrane antigen (PSMA) or the somatostatin-2 receptor, are each approved for only a single tumor type, yet have achieved substantial commercial adoption and have become foundational pillars of modern cancer treatment. Despite these advances, the company believes that the radiopharmaceutical field remains in its early stages, with many emerging companies continuing to focus primarily on these same two biological targets. In contrast, the company sees a significant opportunity to expand the range of cancer patients who may benefit from targeted radiopharmaceuticals by developing next-generation technologies designed to broaden the spectrum of tumor targets for which a potent alpha-emitting radioisotope payload can be delivered safely and effectively.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Matthew Roden Ph.D. | President, CEO & Director | — |
| Mr. Todd Foley M.B.A. | Co-Founder & Chairman | 1972 |
| Mr. Kyle D. Kuvalanka | Chief Financial Officer | 1968 |
| Dr. Shulamit Ron-Bigger Ph.D. | Chief Operating Officer | 1981 |
| Dr. Paul L. Feldman Ph.D. | Chief Scientific Officer | 1962 |
| Dr. Akos Czibere M.D., Ph.D. | Chief Medical Officer | 1978 |
| Dr. Patrick A. Baeuerle Ph.D. | Co-Founder & Member of Scientific Advisory Board | 1958 |
| Dr. Tyler Benedum Ph.D. | Chief Technical Officer | 1977 |
| Mr. Carlos Rodriguez | Executive Director of Corporate Development | — |
| Dr. Dasa Lipovsek Ph.D. | VP & Head of Lead Discovery | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of October 23, 2026
Technical indicators
- RSI 14
- 36.51
- MACD 12/26/9
- -1.58
- EMA 9 of MACD
- -1.69
- MACD histogram
- 0.11
- SMA 50
- $21.57
- Price below SMA 50
- EMA 50
- $20.18
- Price below EMA 50
Calculated by Gotrade from daily closing prices, as of October 22, 2026. Technical data, not a recommendation.
Analyst views
3 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $35.00
- Average
- $37.33
- High
- $40.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | +1.6 | -8.8 | -0.1 | |||||||||
| 2022 | -13.7 | +2.8 | +5.3 | -32.1 | -10.9 | -5.1 | +18.6 | +0.2 | -30.6 | +8.8 | +11.1 | -23.6 |
| 2023 | +32.3 | -2.6 | -13.0 | -8.1 | +10.1 | +1.0 | -25.3 | -35.5 | -50.7 | -28.2 | +9.6 | +45.6 |
| 2024 | -28.8 | +12.7 | -1.7 | +7.3 | -63.3 | -31.6 | +0.0 | -27.3 | +12.5 | -25.0 | +100.0 | -60.0 |
| 2026 | -9.6 | -8.4 | -10.5 | +9.8 | +6.8 | +65.5 | -28.6 | +16.6 | -25.1 | -11.3 |
